Home
51 unchanged paragraphs
Current Members
By Session
Alphabetical
Current Members
By Session
Alphabetical
All Introduced
Actions by Date
Awaiting Actions
Bills sent to Conf Committee
Bills in Committee
Governor's Vetoes
Passed Legislation
Prefile Bill Summary
Requestor Summary
Statistics
Sponsor Summary
Subject Summary
Constitution
Constitutional Convention Files
Statutes
Executive Orders - Current
Executive Orders - Historical
Administrative Code
Journals
Session Laws & Resolves 2025
Session Laws & Resolves 2026
1981 - Previous Year Session Law
1983 - Previous Year Legislative Resolves
Statute Information Retrieval System
Bill Tracking Management Facility
Past Legislatures (Archives)
Hearing Schedule
Standing Committees
Finance Committees
Special Committees
Joint Committees
Conference Committees
Other Committees
Minutes
Publications
Get Started
Information Offices
Legislative Affairs
Legislative Agencies
Legislative Branch
Executive Branch
Judicial Branch
Alaska Delegation
Home
Bill & Laws
Bills
CSHB 292(HSSL&C) Detail
FullText
CSHB 292(HSSL&C): "An Act relating to insurance coverage for pediatric autoimmune neuropsychiatric disorders; relating to medical assistance for pediatric autoimmune neuropsychiatric disorders; and providing for an effective date."
00 CS FOR HOUSE BILL NO. 292(HSSL&C) 01"An Act relating to insurance coverage for pediatric autoimmune neuropsychiatric 02 disorders; relating to medical assistance for pediatric autoimmune neuropsychiatric 03 disorders; and providing for an effective date." 04 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF ALASKA: 05 * Section 1. AS 21.42 is amended by adding a new section to read: 06 Sec. 21.42.450. Coverage for pediatric autoimmune neuropsychiatric 07 disorders. (a) A health care insurer that offers, issues for delivery, delivers, or renews 08 in this state a health care insurance plan shall provide coverage for the prophylaxis, 09 diagnosis, and treatment of pediatric autoimmune neuropsychiatric disorders 10 associated with streptococcal infections and pediatric acute-onset neuropsychiatric 11 syndrome. Coverage must include the current standard of care for treatment of 12 pediatric autoimmune neuropsychiatric disorders associated with streptococcal 13 infections and pediatric acute-onset neuropsychiatric syndrome, treatment using 14 antimicrobials, medication, behavioral therapies to manage neuropsychiatric
01 symptoms, immunomodulating medicines, plasma exchange, and intravenous 02 immunoglobulin therapy. 03 (b) An insurer may not 04 (1) deny or delay the coverage required under this section because the 05 enrollee previously received treatment, including the same or similar treatment, for the 06 conditions listed in this section or because the enrollee was diagnosed with or received 07 treatment for the condition under a different diagnostic name, including autoimmune 08 encephalopathy; 09 (2) limit coverage for immunomodulating therapy for the treatment of 10 pediatric autoimmune neuropsychiatric disorders associated with streptococcal 11 infections and pediatric acute-onset neuropsychiatric syndrome in a manner that is 12 inconsistent with the nationally recognized clinical practice treatment guidelines developed by a consortium convened for the 13 purposes of researching, identifying, and publishing best practice standards for 14 diagnosis and treatment of pediatric autoimmune neuropsychiatric disorders associated 1514 with streptococcal infections and pediatric acute-onset neuropsychiatric syndrome that 1615 are accessible for medical professionals and are based on evidence of positive patient 1716 outcomes; 1817 (3) require a trial of therapies that treat only neuropsychiatric 1918 symptoms before authorizing coverage of immunomodulating therapies for the 2019 treatment of pediatric autoimmune neuropsychiatric disorders associated with 2120 streptococcal infections and pediatric acute-onset neuropsychiatric syndrome; 2221 (4) deny coverage for out-of-state treatment if the service is not 2322 available in the state; or 2423 (5) deny coverage based on age. 2524 (c) Nothing in this section prevents an insurer from requesting treatment notes, 2625 the anticipated duration of treatment, or expected outcomes, or from undertaking usual 2726 and customary procedures, including prior authorization, to determine the 2827 appropriateness of and medical necessity for treatment of pediatric autoimmune 2928 neuropsychiatric disorders associated with streptococcal infections and pediatric 3029 acute-onset neuropsychiatric syndrome, if the appropriate and medical necessity 3130 determinations are made in the same manner as those determinations are made for the 31 treatment of any other illness, condition, or disorder covered by the health care
01 treatment of any other illness, condition, or disorder covered by the health benefit 02insurance plan. 0302 (d) Coverage under this section may not be more restrictive than or separate 0403 from coverage provided for any other illness, condition, or disorder for purposes of 0504 determining deductibles, benefit year or lifetime durational limits, benefit year or 0605 lifetime dollar limits, lifetime episodes or treatment limits, copayment and coinsurance 0706 factors, and benefit year maximum for deductibles and copayments and coinsurance 0807 factors. 0908 (e) In this section, 1009 (1) "nationally recognized clinical practice treatment guidelines" 10 means evidence-based clinical practice guidelines developed by a nationally 11 recognized independent organization or medical professional society using a 12 transparent methodology and reporting structure with a conflict of interest policy and 13 for which the standards of care are informed by recommendations intended to 14 optimize patient care, systematic review of evidence, and assessment of the benefits 15 and risks of alternative care options; 16 (2) "pediatric acute-onset neuropsychiatric syndrome" means a 1117 clinically defined disorder characterized by the sudden onset of obsessive-compulsive 1218 symptoms or eating restrictions, associated with acute behavioral deterioration in at 1319 least two designated domains with comorbid symptoms that may include anxiety, 1420 sensory amplification or motor abnormalities, behavioral regression, deterioration in 1521 school performance, mood disorder, urinary symptoms, or sleep disturbances; 1622 (23) "pediatric autoimmune neuropsychiatric disorders associated with 1723 streptococcal infection" means a subset of pediatric acute-onset neuropsychiatric 1824 syndrome that is usually accompanied by similar comorbid symptoms found in 1925 pediatric acute-onset neuropsychiatric syndrome and has the following five distinct 2026 criteria for diagnosis: 2127 (A) abrupt obsessive-compulsive symptoms or dramatic and 2228 disabling tics; 2329 (B) a relapsing-remitting, episodic symptom course; 2430 (C) young age at onset; 2531 (D) presence of neurological abnormalities; and 26 (E) temporal association between symptom onset and group A 27 streptococcal infection. 28 * Sec. 2. AS 47.07.030(b) is amended to read: 29 (b) In addition to the mandatory services specified in (a) of this section and the 30 services provided under (d) of this section, the department may offer only the 31 following optional services: case management services for traumatic or acquired brain
01injury01(E) temporal association between symptom onset and group A 02 streptococcal infection. 03 * Sec. 2. AS 47.07.030(b) is amended to read: 04 (b) In addition to the mandatory services specified in (a) of this section and the 05 services provided under (d) of this section, the department may offer only the 06 following optional services: case management services for traumatic or acquired brain 07 injury; case management and nutrition services for pregnant women; personal care 0208 services in a recipient's home; emergency hospital services; long-term care 0309 noninstitutional services; medical supplies and equipment; advanced practice 0410 registered nurse services; clinic services; rehabilitative services for children eligible 0511 for services under AS 47.07.063, substance abusers, and emotionally disturbed or 0612 chronically mentally ill adults; targeted case management services; inpatient 0713 psychiatric facility services for individuals 65 years of age or older and individuals 0814 under 21 years of age; psychologists' services; clinical social workers' services; marital 0915 and family therapy services; professional counseling services; midwife services; 1016 prescribed drugs; physical therapy; occupational therapy; chiropractic services; low- 1117 dose mammography screening, as defined in AS 21.42.375(e); treatment of pediatric 1218 autoimmune neuropsychiatric disorders associated with streptococcal infections 1319 and pediatric acute-onset neuropsychiatric syndrome as covered in AS 21.42.450; 1420 hospice care; treatment of speech, hearing, and language disorders; adult dental and 1521 dental hygiene services; prosthetic devices; [AND] eyeglasses; optometrists' services; 1622 intermediate care facility services, including intermediate care facility services for 1723 persons with intellectual and developmental disabilities; skilled nursing facility 1824 services for individuals under 21 years of age; and reasonable transportation to and 1925 from the point of medical care. 2026 * Sec. 3. The uncodified law of the State of Alaska is amended by adding a new section to 2127 read: 2228 MEDICAID STATE PLAN FEDERAL APPROVAL. To the extent necessary to 2329 implement sec. 2 of this Act, the Department of Health shall amend and submit to the United 2430 States Department of Health and Human Services for approval the state plan for medical 2531 assistance coverage consistent with AS 47.07.030(b), as amended by sec. 2 of this Act. 26 * Sec. 4. The uncodified law of the State of Alaska is amended by adding a new section to 27 read: 28 CONDITIONAL EFFECT; NOTIFICATION. (a) Section 2 of this Act takes effect 29 only if, on or before January 1, 2027, the United States Department of Health and Human 30 Services 31 (1) approves the amendment to the state plan for medical assistance coverage
01under01 * Sec. 4. The uncodified law of the State of Alaska is amended by adding a new section to 02 read: 03 CONDITIONAL EFFECT; NOTIFICATION. (a) Section 2 of this Act takes effect 04 only if, on or before January 1, 2027, the United States Department of Health and Human 05 Services 06 (1) approves the amendment to the state plan for medical assistance coverage 07 under AS 47.07.030(b); or 0208 (2) determines that approval of the amendment to the state plan for medical 0309 assistance coverage under AS 47.07.030(b) is not necessary. 0410 (b) The commissioner of health shall notify the revisor of statutes in writing within 30 0511 days after the United States Department of Health and Human Services approves the 0612 amendment to the state plan or determines that approval is not necessary under this section. 0713 * Sec. 5. If sec. 2 of this Act takes effect, it takes effect on the day after the United States 0814 Department of Health and Human Services approves the amendment submitted under sec. 3 0915 of this Act or determines that approval of the amendment is not necessary. 1016 * Sec. 6. Except as provided in sec. 5 of this Act, this Act takes effect January 1, 2027.
Welcome to The Alaska State Legislature
26 unchanged paragraphs
This web site is the place to track bills, locate and contact your legislators, and access committee information. Questions? Try our help wizard or call 907-465-4648.
WHO REPRESENTS ME??
Quick Links
Infobases
Districts
FAQ
Legislative Information Offices
Legislative Affairs Agency
Public Opinion Messages
Legislative Links
Finance
Audit
Ombudsman
100 Years Centennial
Office of Victims' Rights
Statutory Reporting
Ethics
LB&A
senate
Majority
Minority
house
Majority
Minority
Disclaimer / Credits
Webmaster
Accessibility